Themis Medicare Upgraded to 'Hold' Amid Bullish Trend, But Concerns Remain

Themis Medicare, a smallcap pharmaceutical company, has recently been upgraded to a 'Hold' by MarketsMOJO on July 9, 2024. This upgrade comes as the stock has shown a bullish trend and has consistently outperformed the BSE 500 index in the last 3 years. The technical trend for Themis Medicare has improved from mildly bullish to bullish on July 9, 2024. The stock's MACD and Bollinger Band technical factors are also showing a bullish trend. However, the company's high debt to EBITDA ratio of 7.47 times raises concerns about its ability to service its debt. In terms of long-term growth, Themis Medicare has not shown promising results. Its net sales have only grown at an annual rate of 15.75% over the last 5 years. Additionally, the company has declared negative results for the last 3 consecutive quarters, with a -35.87% growth in PAT (9M) and a low ROCE (HY) of 13.27%. With a ROCE of 8.6, the stock is currently trading at a very expensive valuation with an enterprise value to capital employed ratio of 5.1. This is significantly higher than its average historical valuations. Despite generating a return of 59.52% in the past year, the company's profits have fallen by -23.5%. It is also worth noting that despite its smallcap size, domestic mutual funds hold only 0% of the company. This could indicate that they are either not comfortable with the current price or have concerns about the company's business. In conclusion, while Themis Medicare has shown a bullish trend and consistent returns in the past, its high debt and poor long-term growth raise concerns. The stock's expensive valuation and lack of interest from domestic mutual funds also suggest caution for potential investors.